Challenges Emerge for Semaglutide as GLP-1 Drugs Struggle with Long-Term Adherence

2024-07-12

In the weight-loss drug market, semaglutide was once seen as a rising star driving growth. However, a recent in-depth analysis has raised doubts about this growth trajectory. According to research by Prime Pharmacy Benefit Management, over 85% of GLP-1 weight-loss drug users choose to discontinue treatment after two years, posing a challenge to semaglutide's growth prospects.

Prime's study, based on insurance claims data from around 3,400 patients diagnosed with obesity or a BMI over 30 (excluding those with diabetes), found that female patients accounted for a high 81% of the cohort, who started taking GLP-1 medications from 2021 and remained enrolled in commercial insurance plans.

The research revealed a significant decline in patient persistence over time. Only 47% of patients continued treatment after six months, 29% after one year, and a mere 14.8% after two years. The situation was equally bleak for those taking weekly injection weight-loss shots, with around three-quarters of users of Novo Nordisk's Wegovy and Eli Lilly's Ozempic opting to discontinue at some point.

This trend highlights the stark contrast between clinical trial results and real-world application. In Novo Nordisk's trials for semaglutide, 77% of patients were still using the target dose after two years. However, in the real world, patient adherence is influenced by factors such as high treatment costs, drug supply shortages, and side effects.

The high cost of these weight-loss injections, with monthly prices exceeding $1,000 in the US, is a significant driver of patient discontinuation, as it places a heavy financial burden on long-term use. Additionally, the potential side effects of semaglutide, including gastrointestinal symptoms and mental health issues such as depression and bipolar disorder, contribute to patients' decisions to stop taking the drug.

Faced with this challenge, Novo Nordisk has questioned the data, arguing that it does not fully reflect the overall dependence and persistence of patients on GLP-1 medications. However, regardless of the ongoing debate, semaglutide's growth prospects are undoubtedly facing considerable hurdles.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构